Valentino Leonard A, Oza Veeral M
RUSH Hemophilia and Thrombophilia Center, Department of Pediatrics, Rush University Medical Center, Chicago, Illinois 60612, USA.
Pediatr Blood Cancer. 2006 Sep;47(3):245-54. doi: 10.1002/pbc.20895.
Hemophilia is a congenital disorder due to the deficiency of the activity of factor VIII (classical hemophilia A) or IX (Christmas disease or hemophilia B). Bleeding is common and may result in long-term complications or even death. Bleeding may be treated or prevented by infusion of factor concentrates however these drugs are not without risk. Clinicians often feel ill prepared to provide accurate and impartial information regarding these drugs. This review will provide the reader with an historical yet up to date perspective on blood safety as it relates to the choice of concentrates to treat hemophilia.
血友病是一种先天性疾病，由于缺乏凝血因子VIII（经典血友病A）或IX（克里斯马斯病或血友病B）的活性所致。出血很常见，可能导致长期并发症甚至死亡。输注凝血因子浓缩物可治疗或预防出血，然而这些药物并非没有风险。临床医生常常觉得没有充分准备好提供有关这些药物的准确和公正的信息。本综述将为读者提供一个与治疗血友病的浓缩物选择相关的血液安全方面的历史及最新观点。
